{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:39:18Z","timestamp":1790854758096,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.schres.2017.07.037","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T01:30:14Z","timestamp":1501119014000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Hyperprolactinaemia in first episode psychosis - A longitudinal assessment"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3038-0625","authenticated-orcid":false,"given":"John","family":"Lally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olesya","family":"Ajnakina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Carra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Gardner-Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerrin","family":"Atakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalida","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubalade","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Gaughran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.schres.2017.07.037_bb0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.pnpbp.2010.02.019","article-title":"Hyperprolactinaemia in early psychosis\u2014not only due to antipsychotics","volume":"34","author":"Aston","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.07.037_bb0010","unstructured":"Bayer Diagnostics, ADVIA centaur assay manual, Revision AT."},{"issue":"12 Suppl","key":"10.1016\/j.schres.2017.07.037_bb0015","first-page":"1075","article-title":"Guidelines for the diagnosis and treatment of hyperprolactinemia","volume":"44","author":"Biller","year":"1999","journal-title":"J. Reprod. Med."},{"issue":"3","key":"10.1016\/j.schres.2017.07.037_bb0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0165-1781(81)90078-0","article-title":"Tolerance to the prolactin-elevating effect of neuroleptics","volume":"5","author":"Brown","year":"1981","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2017.07.037_bb0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0447.1990.tb01360.x","article-title":"The list of threatening experiences: the reliability and validity of a brief life events questionnaire","volume":"82","author":"Brugha","year":"1990","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.schres.2017.07.037_bb0030","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics","volume":"21","author":"Bushe","year":"2007","journal-title":"J. Psychopharmacol."},{"issue":"2 suppl","key":"10.1016\/j.schres.2017.07.037_bb0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"2 Suppl","key":"10.1016\/j.schres.2017.07.037_bb0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881107088436","article-title":"Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics","volume":"22","author":"Bushe","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2017.07.037_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2307\/2136404","article-title":"A global measure of perceived stress","volume":"24","author":"Cohen","year":"1983","journal-title":"J. Health Soc. Behav."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.07.037_bb0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.schres.2013.08.036","article-title":"Vitamin D deficiency in first episode psychosis: a case-control study","volume":"150","author":"Crews","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.07.037_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.1265","article-title":"Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications","volume":"27","author":"Crews","year":"2012","journal-title":"Hum. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.07.037_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/acps.12459","article-title":"Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review","volume":"133","author":"De Hert","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.schres.2017.07.037_bb0065","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","article-title":"Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders","volume":"115","author":"Eberhard","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2017.07.037_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2011.07.025","article-title":"Prolactin concentrations in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis","volume":"134","author":"Garcia-Rizo","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.07.037_bb0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2016.03.018","article-title":"Prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders: a meta-analysis","volume":"174","author":"Gonzalez-Blanco","year":"2016","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2017.07.037_bb0080","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1210\/endo.142.9.8385","article-title":"Feedback regulation of PRL secretion is mediated by the transcription factor, signal transducer, and activator of transcription 5b","volume":"142","author":"Grattan","year":"2001","journal-title":"Endocrinology"},{"issue":"20","key":"10.1016\/j.schres.2017.07.037_bb0085","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.schres.2017.07.037_bb0090","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2017.07.037_bb0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.jcp.0000162798.87249.4d","article-title":"Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment","volume":"25","author":"Howes","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2017.07.037_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4088\/JCP.v68n0302","article-title":"Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder","volume":"68","author":"Howes","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"9618","key":"10.1016\/j.schres.2017.07.037_bb0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.schres.2017.07.037_bb0110","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2017.07.037_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation","volume":"7","author":"Kay","year":"1989","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"1","key":"10.1016\/j.schres.2017.07.037_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1440-1819.2008.01907.x","article-title":"Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study","volume":"63","author":"Kwon","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2017.07.037_bb0125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12888-016-0780-2","article-title":"Clinical correlates of vitamin D deficiency in established psychosis","volume":"16","author":"Lally","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2017.07.037_bb0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":"Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur. Psychiatry"},{"issue":"9896","key":"10.1016\/j.schres.2017.07.037_bb0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.schres.2017.07.037_bb0140","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/archpsyc.1991.01810320088015","article-title":"A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system","volume":"48","author":"McGuffin","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2017.07.037_bb0145","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia","volume":"184","author":"Meaney","year":"2004","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.07.037_bb0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.schres.2017.07.037_bb0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.07.037_bb0160","series-title":"Psychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178)","author":"NICE","year":"2014"},{"issue":"2 suppl","key":"10.1016\/j.schres.2017.07.037_bb0165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","article-title":"Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia","volume":"22","author":"O'Keane","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2017.07.037_bb0170","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","article-title":"Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis","volume":"32","author":"P\u00e9rez-Iglesias","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.07.037_bb0175","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.schres.2017.07.037_bb0180","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-R\u00f6ssler","year":"2013","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.schres.2017.07.037_bb0185","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial","volume":"162","author":"Schooler","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.07.037_bb0190","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.07.037_bb0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.genhosppsych.2015.01.004","article-title":"Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis","volume":"37","author":"Stubbs","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.schres.2017.07.037_bb0200","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"WHO","year":"1992"},{"key":"10.1016\/j.schres.2017.07.037_bb0205","series-title":"Guidelines for ATC Classification and DDD Assignment","year":"2015"},{"key":"10.1016\/j.schres.2017.07.037_bb0210","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1992"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417304486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417304486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T13:27:55Z","timestamp":1569936475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417304486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":42,"alternative-id":["S0920996417304486"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.07.037","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprolactinaemia in first episode psychosis - A longitudinal assessment","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}